Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Details 詳細情報について

• CRID

  1360013170485023360

• DOI

  10.1016/s1470-2045(21)00151-0

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204521001510?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204521001510?httpAccept=text/plain

• Data Source

  • Crossref